Last Updated: May 1, 2026

Claims for Patent: 6,784,347

✉ Email this page to a colleague

Summary for Patent: 6,784,347

Title:	Hybrid maize plant and seed 33R77
Abstract:	According to the invention, there is provided a hybrid maize plant, designated as 33R77, produced by crossing two Pioneer Hi-Bred International, Inc. proprietary inbred maize lines. This invention relates to the hybrid seed 33R77, the hybrid plant produced from the seed, and variants, mutants, and trivial modifications of hybrid 33R77. This invention also relates to methods for producing a maize plant containing in its genetic material one or more transgenes and to the transgenic maize plants produced by that method. This invention further relates to methods for producing maize lines derived from hybrid maize line 33R77 and to the maize lines derived by the use of those methods.
Inventor(s):	David L. Benson
Assignee:	Pioneer Hi Bred International Inc
Application Number:	US09/759,748

Details for Patent 6,784,347

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	February 06, 2009	⤷ Start Trial	2021-01-12
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	April 11, 2014	⤷ Start Trial	2021-01-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.